News

Regeneron Pharmaceuticals Quarterly Update and Conference Call

Regeneron Pharmaceuticals Quarterly Update and Conference Call

Regeneron Pharmaceuticals to Announce First Quarter 2025 Results

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced an important event on the horizon regarding its financial and operational updates for the first quarter of 2025. This event is set to take place on the morning of April 29, 2025, just before the start of the U.S. financial markets. Investors and interested parties will have the opportunity to engage with the company's latest progress and insights during this period.

Details of the Upcoming Event

The conference call and webcast will commence at 8:30 AM Eastern Time on the aforementioned date. Participants will be able to access the live discussion through Regeneron's official website on their 'Investors and Media' page. In addition, those choosing to join via phone must register in advance, ensuring a seamless experience for all those interested in participating.

How to Access the Call

Individuals wishing to join the conference call are encouraged to visit the designated area on Regeneron’s website for further details. Upon registration, participants will receive a confirmation email which will outline the process for joining the call, including specific dialing instructions and a unique passcode. This level of accessibility showcases Regeneron’s commitment to transparency and investor relations.

About Regeneron Pharmaceuticals

Founded by a team of physician-scientists, Regeneron is dedicated to the invention, development, and commercialization of transformative medicines for individuals with serious health conditions. The company is redefining the future of biotechnology through its innovative research and development processes.

Regeneron’s Advancements in Biotechnology

Regeneron stands out as a pioneer in the biotechnology industry, utilizing proprietary technologies that have enabled the creation of life-changing treatments. Their VelociSuite technology empowers the rapid development of fully human antibodies, in addition to new classes of bispecific antibodies. This dedication to science and innovation is not only notable but is leading the way towards the next generation of medical solutions.

The Company’s Broader Impact

With a robust pipeline designed to tackle a variety of diseases, Regeneron's reach extends across multiple areas including eye diseases, allergic conditions, cancer, cardiovascular issues, and rare diseases. The firm's commitment to addressing these critical health concerns illustrates its role as a leader in the field.

Insights from the Regeneron Genetics Center

Data-driven insights from the Regeneron Genetics Center are shaping the company’s strategic approach. This focus on genetics enables Regeneron to discover novel therapeutic targets and innovative pathways that could potentially yield cures for various diseases. This forward-thinking mindset is what sets Regeneron apart in the competitive biotechnology landscape.

Contact Information for Investors

For those interested in more detailed information, Regeneron has made it simple to reach out for inquiries. The dedicated Investor Relations team, led by Ryan Crowe, can be contacted at 914.847.8790 or through email at ryan.crowe@regeneron.com. Furthermore, Corporate Communications inquiries can be directed to Christina Chan at 914.847.8827 or via email at christina.chan@regeneron.com.

Frequently Asked Questions

What is the date of Regeneron's first quarter call?

The first quarter call is scheduled for April 29, 2025.

How can I participate in the conference call?

You can participate by accessing the live webcast on Regeneron's 'Investors and Media' page or by registering for the telephone call in advance.

What innovative technologies does Regeneron use?

Regeneron utilizes proprietary technologies like VelociSuite to develop advanced therapeutic solutions.

Who can I contact for more information?

Investors can reach out to Ryan Crowe or Christina Chan for inquiries regarding Regeneron.

What types of diseases does Regeneron target?

Regeneron develops therapies for a wide range of conditions including cancer, eye diseases, and rare diseases.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Emdoor’s Rugged Devices Fuel Industry Growth Globally

Updated Category News Views 7

Emdoor Information: A Sturdy Path in Rugged Computing Dive into the heart of the rugged computing terrain, and you may very well run into Emdoor Information—an 18-year-old titan from Shenzhen that’s carved its niche on the backs of rugged tablets, laptops, and handhelds. Publicly listed since 2023 on China’s A-share main board, Emdoor isn't just any player in this...

Continue Reading
NOARK: Powering Data Centers with Global-Local Approach

Updated Category News Views 6

The High-Stakes Race for Data Center Power These days, if you're not talking about data centers, you're probably a step behind the curve. AI's explosive growth is pushing data center developments across North America like never before. Larger campuses, hefty power densities—it's all happening at a pace that's got everyone scrambling. For folks like NOARK Electric, this...

Continue Reading
Phoenix Scholar Examines AI and Institutional Trust

Updated Category News Views 6

A Thoughtful Look at Trust and Technology We're staring at an issue here that dives deep into the guts of how technology, AI in particular, is reshaping our professional landscape. The latest issue of the Phoenix Scholar, a publication from the University of Phoenix College of Doctoral Studies, is tackling big questions. It's that kind of brainy reading where you untangle...

Continue Reading
Zoomlion Boosts Mining Gear Amid Global Revenue Surge

Updated Category News Views 8

An Ambitious Expansion Overhaul Alright, let's talk Zoomlion Heavy Industry Science & Technology Co., Ltd. They're not just making a splash; they're wading knee-deep into expanding their mining machinery operations and taking charge in international markets. You see, in the first half of 2026, this Chinese behemoth saw its mining machinery business skyrocket by over...

Continue Reading
AI in Music: CITY JAM Focuses on Human Creativity

Updated Category News Views 6

Breaking Down the AI Music Race In the wild world of music production, AI's making waves. Here's the thing though—it's all about how fast and how much it can churn out. Now, won't lie to you, that's impressive, but not the full picture. Pat Villaceran, the brain behind CITY JAM, is adamant that the real gold isn't just speed. It's the unique sound each artist brings to...

Continue Reading
CenterPoint Deploys Crews for Hurricane Aid Relief

Updated Category News Views 4

CenterPoint’s Commitment Amidst Crisis Now, when a hurricane slams into the coast, it’s go time for everyone in the game. CenterPoint Energy, never one to sit on the sidelines, is showing up with a hefty squad to help fix the mess left by Hurricane Isaias. A robust 355-strong team is heading out to assist with power restoration down there in Florida. This isn’t just...

Continue Reading
tm:rw Revolutionizes Retail with Live TikTok Studios

Updated Category News Views 4

tm:rw Takes a Bold Step into Social Commerce Throw out whatever you've thought about traditional brick-and-mortar retail because tm:rw isn't just bending the rules—it's burning the book. Launching nine branded studio spaces at their Times Square flagship, tm:rw is blending live streaming with in-person shopping, all in sync with TikTok Shop. The experience is less about...

Continue Reading
Tchah Sup Kim: A Retrospective at KCCNY in 2026

Updated Category News Views 4

A Glimpse into Tchah Sup Kim's Legacy Stumble into the world of Tchah Sup Kim (1940–2022) this fall at the Korean Cultural Center New York. Kim's posthumous retrospective, "The Key to a New World," brings together over 130 of his works alongside archival materials, offering a comprehensive dive into a mind that spent decades between New York and Korea. The exhibit,...

Continue Reading
APsystems Unveils C&I Storage Solutions at SEF 2026

Updated Category News Views 6

APsystems Puts the Spotlight on Advanced Storage Move over, traditional energy solutions—APsystems is stepping into the future with a bang at the Smart Energy Forum 2026 in Prague. Set your sights on the latest advancements in solar and energy storage solutions as the company unveils its comprehensive offerings. If you’re hanging around the PVA EXPO PRAHA on October...

Continue Reading
Kailas Campaign Binds Climbers with Gear, Trust

Updated Category News Views 5

Embracing the Spirit of Climbing Connections Alright, so when's the last time you saw a brand digging into the human side of one rugged sport like climbing? That's where Kailas steps in, pulling us beyond gear talk into the trust and camaraderie that defines climbing. Their latest effort—dubbed “Stay Warm, Stay Together”—goes beyond mere technical prowess by...

Continue Reading

Top 5 Most Recently Viewed Articles

MINISO Group's Remarkable Growth: Q3 2025 Financial Overview

Updated Category News Views 271

Financial Performance Overview MINISO Group Holding Limited (NYSE: MNSO) has showcased robust growth in its unaudited financial performance for the most recent quarter. The company achieved a striking 28.2% year-on-year increase in revenue, amounting to RMB5,796.6 million (approximately US$814.3 million). This surge surpassed the higher end of the company's previous...

Continue Reading
Rhine Air Welcomes Andrew Conant as Director of Business Operations

Updated Category News Views 165

Rhine Air Welcomes a New Leader to the Team The new role signals the organization's renewed commitment to Rhine Air's continued growth in the market. Introducing Andrew Conant Rhine Air, a leader in advanced ventilation and respiratory solutions, is elated to announce that Andrew Conant has joined the team as the Director of Business Operations. In this crucial position,...

Continue Reading
Important Legal Information for Intellia Therapeutics Investors

Updated Category News Views 315

Understanding the Intellia Therapeutics Class Action Investors in Intellia Therapeutics, Inc. are urged to take action as significant legal proceedings loom. The Rosen Law Firm, known for advocating investor rights, has announced a class action lawsuit on behalf of shareholders who purchased securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) within a specific...

Continue Reading
F-Secure and TDS Telecom Unite for Advanced Scam Defense

Updated Category News Views 226

F-Secure and TDS Telecom Unite for Advanced Scam Defense TDS Telecom has partnered with F-Secure, a leading name in global cybersecurity, to enhance its Internet Security Suite with advanced scam protection features. This collaboration aims to offer robust defenses against the rising threat of online scams, which have grown both in number and sophistication. With nearly...

Continue Reading
WuXi Biologics Achieves Prestigious MSCI AAA ESG Rating Again

Updated Category News Views 285

WuXi Biologics Celebrates Triple Achievement of MSCI ESG Rating WuXi Biologics (2269.HK), a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), has successfully earned the prestigious AAA ESG rating from Morgan Stanley Capital International (MSCI) for the third consecutive year. This outstanding recognition demonstrates the company's...

Continue Reading